Form 4: United Therapeutics CEO Sells Shares Under 10b5-1 Plan

United Therapeutics CEO Martine Rothblatt executed stock options and sold a portion of the acquired shares under a pre-arranged 10b5-1 trading plan.

Summary

• Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp (UTHR), engaged in transactions involving the company's common stock on October 23 and 24, 2025.
• Rothblatt exercised stock options to acquire 4,000 shares on each day, totaling 8,000 shares, at an exercise price of $120.26 per share.
• Concurrently, Rothblatt sold a total of 8,000 shares of common stock on these dates at weighted average prices ranging from $421.6298 to $426.4 per share.
• These transactions were executed pursuant to a pre-arranged 10b5-1 trading plan established on May 2, 2025.
• The 10b5-1 plan is set to continue until the earlier of the exhaustion of a tranche of 294,000 stock options expiring March 15, 2026, or December 31, 2025.
• Following these transactions, Rothblatt directly holds 130 shares of common stock and indirectly holds 644,393 shares through various family trusts and spouse.
• Rothblatt also holds 154,000 unexercised stock options directly.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While insider selling can sometimes be viewed negatively, the transactions were pre-arranged under a 10b5-1 plan, which is a standard practice for executives to manage their equity compensation and personal finances. It does not reflect a change in the company's fundamental outlook.

Positives

• The transactions were pre-arranged under a 10b5-1 trading plan, indicating a planned diversification or liquidity event rather than a reaction to new, undisclosed information.
• The executive realized significant profits by exercising options at $120.26 and selling shares at prices over $420, demonstrating the value creation from long-term equity compensation.

Negatives

• Insider selling, even when planned, can sometimes be perceived negatively by some investors as it reduces the executive's direct equity stake in the company.

Future Outlook

The pre-arranged 10b5-1 trading plan, under which these transactions occurred, is scheduled to continue until the earlier of the exhaustion of a tranche of 294,000 stock options expiring March 15, 2026, or December 31, 2025, indicating potential future similar transactions.

Management Comments

• The exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on May 2, 2025.

Industry Context

This filing represents a routine insider transaction, common for executives to manage their equity compensation and diversify personal holdings. The use of a 10b5-1 plan is a standard practice to execute such transactions in a pre-scheduled and compliant manner, mitigating concerns about trading on material non-public information.

Related Party Transactions

• Indirect beneficial ownership of 644,393 shares through various family trusts and spouse, where the reporting person and/or immediate family members are beneficiaries or have shared investment power.

Stakeholder Impact

• Shareholders may view the planned insider selling as a routine diversification of holdings by a long-serving executive, especially given the significant profit realized from the option exercises.
• The existence of a 10b5-1 plan provides transparency and mitigates concerns about opportunistic trading.

Next Steps

• The 10b5-1 trading plan will continue until the earlier of the exhaustion of a tranche of 294,000 stock options that expire March 15, 2026, or December 31, 2025, suggesting further planned transactions may occur.

Key Dates

Recommendation

The filing details routine insider transactions executed under a pre-arranged 10b5-1 trading plan. These planned sales for diversification or liquidity purposes by an executive do not typically signal a change in the company's fundamental prospects or warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate as the filing does not provide new information to alter the existing investment outlook for United Therapeutics.

Keywords

United Therapeutics, UTHR, Martine Rothblatt, Insider Trading, Form 4, Stock Options, 10b5-1 Plan, Share Sale, CEO